GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer.
"We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption."
Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management.
"I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors."
Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas.
Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC.
GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1
About GT Medical Technologies, Inc.GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.
About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.
Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X.
Media ContactDawn FallonNew Dawn Communications LLCDfallon@newdawncomms.com732-771-7808
References
Garcia MA et al. J Neurooncol. 166:203-212 (2024).
View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-medical-technologies-names-james-leech-chief-financial-and-strategy-officer-302477192.html
SOURCE GT Medical Technologies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
GUINNESS AND VAN LEEUWEN CHURN OUT THE ULTIMATE LOVELY DAY ICE CREAM COLLAB
From scoop shops to surf shops, Guinness is bringing lovely days across the country all summer long! NEW YORK, July 21, 2025 /PRNewswire/ -- Two icons. One delicious collaboration. Guinness and Van Leeuwen are serving up lovely days by the scoop! The brands have teamed up to churn out the ultimate ice cream collab of the summer and prove that Guinness was made for sunny days too. The launch of the "Lovely Day for a Guinness" ice cream combines Van Leeuwen's ultra-creamy ice cream with the unforgettable flavor of Guinness mixed with rich chocolate chunks. It's bold. It's unexpected. And it's everything a summer treat should be! Inspired by the classic "Lovely Day for a Guinness" ads of the 1950s, the aptly named limited-edition ice cream pays homage to that same legacy while offering a new way to enjoy the brand during the summertime. The flavor is packaged in a custom carton, drawing design cues from this summer's limited-edition Guinness Draught Stout 4-pack—available now on shelves nationwide—that reimagines the historic Guinness toucan art with a modern American twist. The "Lovely Day for a Guinness" ice cream 14 oz pint captures the same eye-catching, visual nod to the warmer months. "We're always looking for ways to bring the bold flavor of Guinness to life in new formats, offering a modern twist to a timeless classic," said Karissa Downer, Director, Guinness. "This collaboration with Van Leeuwen captures the simple summer joys that sit at the heart of our "A Lovely Day" campaign – like sharing a scoop of ice cream, a pint of Guinness, and time with the people who make those moments matter. It's one more way to come together over a Guinness and enjoy your lovely days this summer." Starting today, the "Lovely Day for a Guinness" ice cream will be available in 14 oz pints at Van Leeuwen Scoop Shops nationwide for $11.15 or online at with shipping nationwide for $12 while supplies last. Van Leeuwen is known nationally for creative seasonal flavors with a genuine focus on good ingredients and no unnecessary stuff, and for out-of-the-box limited-edition collaboration flavors such as Hidden Valley Ranch, Kraft Macaroni & Cheese, BIGFACE Coffee Affogato in partnership with NBA All-Star Jimmy Butler and Espresso ice cream in partnership with singer/songwriter Sabrina Carpenter. CEO and co-founder Ben Van Leeuwen said: "At Van Leeuwen, we're all about making good ice cream that makes you feel good – and what better way to do that than with Guinness? Their bold, smooth flavor is a perfect match for our rich French-style ice cream, and this collab felt like the kind of lovely-day indulgence that summer calls for. It's unexpected in the best way – and we think people are going to be surprised by how naturally Guinness and ice cream go together." No matter where your lovely days take you, summertime is Guinness time! Beyond the initial launch with Van Leeuwen, Guinness is showing up to celebrate the many ways people enjoy their lovely days under the sun: Scoop Shop & Sampling Events: Here's how to score free ice cream this summer! Guinness and Van Leeuwen are teaming up to make your August a little sweeter. On select days, the below locations will offer free samples of the Guinness x Van Leeuwen limited-edition "Lovely Day for a Guinness" flavor, served alongside tiny pours of Guinness Draught while supplies last! Guinness Open Gate Brewery in Chicago: 7/30-8/1 Van Leeuwen Williamsburg Store (204 Wythe Ave, Brooklyn, NY 11249): 8/12 from 5-7 pm Astor Place: 8/14 from 12-8 pm (a Van Leeuwen x Guinness branded ice cream truck will be parked curbside in the area serving ice cream only) Van Leeuwen The Gulch Store (335 11th Ave S, Nashville, TN 37203): 8/15 from 5-7 pm Van Leeuwen Dallas West Village Store (3699 McKinney Ave, Suite 1018, Dallas, TX 75204): 8/22 from 5-7 pm Follow the Pintmobile: Guinness is rolling out a fleet of custom-branded retro vans topped with iconic Guinness surfboards! These retro vans are popping up with treats, tiny pints, and photo-worthy moments so don't miss them when they roll into your neighborhood. Keep your eyes peeled in Miami, Philadelphia, Cincinnati, Columbus and San Diego - it could show up on your corner! Guinness Surf Shop Pop-Up (65 Pier Ave, Hermosa Beach, CA 90254): This August, Guinness is paying homage to the brand's iconic Surfer ad for a lovely day in Hermosa Beach! On 8/9 from 1-7 pm, adults (21+) can stop by SPYDER Surf Shop to taste the "Lovely Day for a Guinness" Van Leeuwen ice cream collab, enjoy tiny pints of Guinness Draught alongside tiny tacos from a local favorite joint and grab exclusive summer merch. As a thank you to the Hermosa Beach community for celebrating with us, Guinness is making a $20,000 donation to the Surfrider Foundation to help protect and preserve the coastline that's the backdrop to countless lovely days. Follow @GuinnessUS across social media to stay up to date on all the lovely days and local activities this summer has to offer. Remember, if you're taking a break or not drinking at all, try a Guinness 0 to keep the celebrations going. Whether you sip or scoop your Guinness, lovely days are ahead all summer long! About Van Leeuwen Ice CreamVan Leeuwen began as a yellow scoop truck on the streets of NYC in 2008 by Ben Van Leeuwen, Pete Van Leeuwen and Laura O'Neill, who were on a mission to make good ice cream from good ingredients that makes you feel good. Their French-style ice cream (made with more than double the amount of egg yolks as standard ice cream) quickly gained a loyal following. Van Leeuwen has since expanded and has scoop shops in New York, California, New Jersey, Pennsylvania, DC, Colorado, Connecticut, Massachusetts, Texas, Tennessee and Florida. Pints, ice cream bars and ice cream sandwiches are available in grocery stores across the country and to order for nationwide shipping from their website. To keep up with everything Van Leeuwen Ice Cream, follow the brand on Instagram @vanleeuwenicecream or visit About GuinnessThe Guinness brand was established in 1759, when Arthur Guinness signed a 9,000 year lease on St. James's Gate Brewery in Dublin. Brewed using four main ingredients, water, barley (malted & roasted), hops and yeast, Guinness is the world's most popular stout. The iconic beer is brewed in 49 countries worldwide and sold in over 150 with almost 9 million glasses of Guinness enjoyed every day around the world. The most GUINNESS is sold in Great Britain, Ireland, USA, Nigeria and Cameroon. More information can be found at About DiageoDiageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Crown Royal, Bulleit and Buchanan's whiskies, Smirnoff, Cîroc and Ketel One vodkas, Casamigos, DeLeon and Don Julio tequilas, Captain Morgan, Baileys, Tanqueray and Guinness. Diageo is listed on both the New York Stock Exchange (NYSE: DEO) and the London Stock Exchange (LSE: DGE) and their products are sold in more than 180 countries around the world. For more information about Diageo, their people, brands, and performance, visit Visit Diageo's global responsible drinking resource, for information, initiatives, and ways to share best practice. Follow Twitter and Instagram for news and information about Diageo North America: @Diageo_NA. MEDIA CONTACTS: Kelly Pepe, diageobeer@ View original content to download multimedia: SOURCE GUINNESS
Yahoo
22 minutes ago
- Yahoo
FDA names former pharmaceutical company executive to oversee US drug program
WASHINGTON (AP) — The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency. FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs. His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement. As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause. Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University. The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs. About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs. FDA's drug center hasn't had a permanent director since January, when Dr. Patrizia Cavazzoni stepped down days before President Donald Trump took office. Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave. FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat. In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March. The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Matthew Perrone, The Associated Press Sign in to access your portfolio
San Francisco Chronicle
23 minutes ago
- San Francisco Chronicle
FDA names former pharmaceutical company executive to oversee US drug program
WASHINGTON (AP) — The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency. FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs. His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement. As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause. Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University. The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs. About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs. Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave. FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat. In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March. The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
